VÍTOVEC, Jiří, Jindřich ŠPINAR and Lenka ŠPINAROVÁ. Heart failure and inhibition of renin-angiotensin-aldosterone system. Cor et Vasa. Amsterdam: Elsevier Science INC, 2018, vol. 60, No 3, p. "E263"-"E273", 11 pp. ISSN 0010-8650. Available from: https://dx.doi.org/10.1016/j.crvasa.2018.02.003.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Heart failure and inhibition of renin-angiotensin-aldosterone system
Authors VÍTOVEC, Jiří (203 Czech Republic, guarantor, belonging to the institution), Jindřich ŠPINAR (203 Czech Republic, belonging to the institution) and Lenka ŠPINAROVÁ (203 Czech Republic, belonging to the institution).
Edition Cor et Vasa, Amsterdam, Elsevier Science INC, 2018, 0010-8650.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30201 Cardiac and Cardiovascular systems
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
RIV identification code RIV/00216224:14110/18:00103230
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.crvasa.2018.02.003
UT WoS 000433252900008
Keywords in English Chronic heart failure; ACE inhibitors; Angiotensin receptor blockers; Mineralocorticoid receptor; antagonists; Aliskiren; Omapatrilat; Sacubitril/valsartan (LCZ 696)
Tags 14110115, 14110211, EL OK, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 10/2/2019 13:23.
Abstract
A historical survey is presented of mortality clinical trials focussed on the inhibition of the renin-angiotensin-aldosterone system on different levels in patients with chronic heart failure. The first study, CONSENSUS, was published in 1987 and showed that the ACE-inhibitor enalapril clearly reduced mortality in severe heart failure compared with placebo. This was followed by studies with beta blockers, angiotensin II type 1 receptor blockers, blockers of mineralocorticoid receptors, and direct renin inhibitors. A recent study, PARADIGM, comparing dual inhibitor of neprilysin and antiotensin II receptor (LCZ 696) with enalapril, was terminated prematurely for a significant effect of inhibiting neprilysin and valsartan. (C) 2018 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.
PrintDisplayed: 25/4/2024 17:23